SCHEMBL3140336

SCHEMBL3140336

Cc1cc(C(C)(C)C)ccc1OCC1CN=C(N)O1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
RECQL P46063 1/20 0.41
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GRM2 Q14416 3/20 0.38
VDR P11473 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
GLA P06280 1/20 0.35
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
PPARG P37231 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3134420 0.90 GRM2 (0.36) KDM4ERECQLALDH1A1GRM2KMT2A
SCHEMBL1516017 0.89 ALOX5AP (0.36) KDM4EGRM2
SCHEMBL1516018 0.89 ALOX5AP (0.36) KDM4EGRM2
SCHEMBL7836938 0.85 L3MBTL1 (0.41) KDM4EALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL7838599 0.83 SCN4A (0.41) ALDH1A1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL1516000 0.83 GRM2 (0.53) KDM4EALDH1A1SMN1; SMN2GRM2KMT2A
SCHEMBL1516115 0.83 GRM2 (0.53) KDM4EALDH1A1SMN1; SMN2GRM2KMT2A
SCHEMBL1515997 0.83 GRM2 (0.53) KDM4EALDH1A1SMN1; SMN2GRM2KMT2A
SCHEMBL3147892 0.81 GRM2 (0.57) ALDH1A1SMN1; SMN2GRM2KMT2ALMNA
SCHEMBL7828716 0.80 ALDH1A1 (0.58) KDM4EALDH1A1GRM2GLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C KDM4E 1354/4885RECQL 501/4885ALDH1A1 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.